Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
|
CN |
|
Federated Hermes Inc
NYSE:FHI
|
US |
|
N
|
Nature Wood Group Ltd
NASDAQ:NWGL
|
MO |
|
G
|
Garden Stage Ltd
NASDAQ:GSIW
|
HK |
|
B
|
Bingo Software Co Ltd
SSE:688227
|
CN |
|
O
|
Odonate Therapeutics Inc
OTC:ODTC
|
US |
Chengdu Olymvax Biopharmaceuticals Inc
Chengdu Olymvax Biopharmaceuticals, Inc. engages in the research and development, manufacture, and sale of human-use vaccines. The company is headquartered in Chengdu, Sichuan and currently employs 440 full-time employees. The company went IPO on 2021-06-08. The firm's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The firm's main customers are center for disease control and prevention (CDC) customers.
Chengdu Olymvax Biopharmaceuticals, Inc. engages in the research and development, manufacture, and sale of human-use vaccines. The company is headquartered in Chengdu, Sichuan and currently employs 440 full-time employees. The company went IPO on 2021-06-08. The firm's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The firm's main customers are center for disease control and prevention (CDC) customers.
